Survival Following Cardiac Transplantation in Patients with Hypertrophic Cardiomyopathy.

06:00 EDT 26th August 2010 | BioPortfolio

Summary of "Survival Following Cardiac Transplantation in Patients with Hypertrophic Cardiomyopathy."

-Heart transplant is a treatment for selected patients with hypertrophic cardiomyopathy (HCM). However, the prevalence, clinical profile and outcome of this subgroup of HCM patients are uncertain. Therefore, we sought to determine the occurrence, clinical characteristics and prognosis of HCM patients who underwent cardiac transplantation in the United States during a 15-year period. METHODS AND
-Demographic, clinical and survival outcome of 26,706 adult (age >/=18 years) heart-only transplant recipients between January 1990 to December 2004 were acquired from the United Network of Organ Sharing (UNOS) Registry. Pre-transplant diagnoses were classified as: HCM (n=303; 1%) and non-HCM (26,403; 99%) [comprised of threepatient subgroups: 1) ischemic cardiomyopathy (n=14,308; 54%); 2) dilated cardiomyopathy (n=11,760; 44%); and 3) restrictive cardiomyopathy (n=335; 1%)]. Study follow-up began at the time of heart transplant and was 76+/-44 months among survivors. The 1-, 5-, and 10-year overall transplant survival for HCM patients was 85%, 75%, and 61%, with a trend toward greater survival compared to non-HCM transplant patients (82%, 70%, 49%; log rank test, p=0.05). However, propensity matched, covariate-adjusted Cox regression model analysis showed better survival over time (p<0.01) among the HCM patients. When HCM post-transplant survival was compared to each of the non-HCM patient subgroups, HCM patients had more favorable survival than those transplanted for ischemic cardiomyopathy (p=0.02). In contrast, HCM post-transplant survival did not differ from those patients transplanted for restrictive (p=0.08) or dilated cardiomyopathy (p=0.25).
-HCM patients comprise a small subset (1%) of the overall population of patients who undergo heart transplantation in the United States. Nonetheless, survival following transplant among HCM patients is comparable to patients transplanted for non-HCM cardiovascular diseases, with possible enhanced survival over time.


1 Hypertrophic Cardiomyopathy Center, Division of Cardiology, Tufts Medical Center, Boston, MA;

Journal Details

This article was published in the following journal.

Name: Circulation. Heart failure
ISSN: 1941-3297


DeepDyve research library

PubMed Articles [35247 Associated PubMed Articles listed on BioPortfolio]

Mitochondrial long noncoding RNAs as blood based biomarkers for cardiac remodeling in patients with hypertrophic cardiomyopathy.

Hypertrophic cardiomyopathy (HCM) is a hereditary heart disease with a high risk for sudden cardiac death in young people. As a subtype, hypertrophic obstructive cardiomyopathy (HOCM) additionally has...

Perioperative outcomes of patients with hypertrophic cardiomyopathy undergoing non-cardiac surgery.

Due to their unique pathophysiological profile, patients with hypertrophic cardiomyopathy (HCM) undergoing non-cardiac surgery require additional attention to perioperative management. We sought to co...

Diffuse Ventricular Fibrosis on Cardiac Magnetic Resonance Imaging Associates with Ventricular Tachycardia in Patients with Hypertrophic Cardiomyopathy.

Non-sustained ventricular tachycardia (NSVT) is a risk factor for sudden cardiac death (SCD) in patients with hypertrophic cardiomyopathy (HCM). We aimed to assess whether diffuse ventricular fibrosis...

Assessment of risk of sudden cardiac death in patients with hypertrophic cardiomyopathy.

Hypertrophic cardiomyopathy (HCM) is a hereditary disease characterized by left ventricular hypertrophy with or without concomitant outflow tract obstruction. Identification of patients with HCM who a...

Is cardiac and hepatic iron status assessed by MRI T2* associated with left ventricular function in patients with idiopathic cardiomyopathy?

Excess accumulation of iron in the heart is known to aggravate cardiac function in some cases of genetic and acquired iron overload. We investigated the possible association between cardiac function a...

Clinical Trials [6603 Associated Clinical Trials listed on BioPortfolio]

The Chinese Hypertrophic Cardiomyopathy Study(CHCS)

Hypertrophic cardiomyopathy (HCM) is one of the most common inherited cardiac diseases, with a prevalence of ∼0.2%. The disease affects all age groups, with marked clinical heterogeneity...

Use of Magnetic Field Mapping in the Evaluation of Patients With Hypertrophic Heart Disease (Thick Heart Muscle)

The purpose of this research study is to further establish the diagnostic use of magnetocardiography (MCG) in patients with hypertrophic cardiomyopathy (HCM). The use of MCG has not been ...

Hypertrophic Cardiomyopathy Pilot Study

This study evaluates mechanisms of arrhythmogenicity in hypertrophic cardiomyopathy, in comparison to patients with well-understood arrhythmogenic substrate (ischemic cardiomyopathy), as w...

Assessment of Wall Thickness in Hypertrophic Cardiomyopathy

Assessment of wall thickness in hypertrophic cardiomyopathy (HCM) is of diagnostic and prognostic importance given its known association with sudden cardiac death. However, data regarding...

Predictive Factors and Consequences of Myocardial Fibrosis in Hypertrophic Cardiomyopathy

Fibrosis, myocardial deformation and biomarkers in hypertrophic cardiomyopathy (HCM)

Medical and Biotech [MESH] Definitions

An autosomal dominant inherited form of HYPERTROPHIC CARDIOMYOPATHY. It results from any of more than 50 mutations involving genes encoding contractile proteins such as VENTRICULAR MYOSINS; cardiac TROPONIN T; ALPHA-TROPOMYOSIN.

A group of diseases in which the dominant feature is the involvement of the CARDIAC MUSCLE itself. Cardiomyopathies are classified according to their predominant pathophysiological features (DILATED CARDIOMYOPATHY; HYPERTROPHIC CARDIOMYOPATHY; RESTRICTIVE CARDIOMYOPATHY) or their etiological/pathological factors (CARDIOMYOPATHY, ALCOHOLIC; ENDOCARDIAL FIBROELASTOSIS).

A form of CARDIAC MUSCLE disease, characterized by left and/or right ventricular hypertrophy (HYPERTROPHY, LEFT VENTRICULAR; HYPERTROPHY, RIGHT VENTRICULAR), frequent asymmetrical involvement of the HEART SEPTUM, and normal or reduced left ventricular volume. Risk factors include HYPERTENSION; AORTIC STENOSIS; and gene MUTATION; (FAMILIAL HYPERTROPHIC CARDIOMYOPATHY).

One of the three polypeptide chains that make up the TROPONIN complex. It is a cardiac-specific protein that binds to TROPOMYOSIN. It is released from damaged or injured heart muscle cells (MYOCYTES, CARDIAC). Defects in the gene encoding troponin T result in FAMILIAL HYPERTROPHIC CARDIOMYOPATHY.

Inflammatory processes of the muscular walls of the heart (MYOCARDIUM) which result in injury to the cardiac muscle cells (MYOCYTES, CARDIAC). Manifestations range from subclinical to sudden death (DEATH, SUDDEN). Myocarditis in association with cardiac dysfunction is classified as inflammatory CARDIOMYOPATHY usually caused by INFECTION, autoimmune diseases, or responses to toxic substances. Myocarditis is also a common cause of DILATED CARDIOMYOPATHY and other cardiomyopathies.

Quick Search

DeepDyve research library

Relevant Topics

Organ transplantation is the moving of an organ from one body to another or from a donor site to another location on the patient's own body, for the purpose of replacing the recipient's damaged or absent organ. The emerging field of regenerative ...

Pulmonary relating to or associated with the lungs eg Asthma, chronic bronchitis, emphysema, COPD, Cystic Fibrosis, Influenza,  Lung Cancer, Pneumonia, Pulmonary Arterial Hypertension, Sleep Disorders etc Follow and track Lung Cancer News ...

Searches Linking to this Article